What is Theralase Technologies Operating Cash Flow per Share?
Theralase Technologies's operating cash flow per share for the
three
months ended in Dec. 2024 was C$-0.00.
Theralase Technologies's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2024 was C$-0.02.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 11.20% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 15.90% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 10.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Theralase Technologies's Operating Cash Flow per Share or its related term are showing as below:
TSXV:TLT'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -141 Med: 4.8 Max: 51.9
Current: 11.2
During the past 13 years, Theralase Technologies's highest 3-Year average Operating Cash Flow per Share Growth Rate was 51.90% per year. The lowest was -141.00% per year. And the median was 4.80% per year.
TSXV:TLT's 3-Year OCF Growth Rate is ranked better than 53.74% of 696
companies
in the Medical Devices & Instruments industry
Industry Median: 8.3
vs TSXV:TLT: 11.20
Theralase Technologies Operating Cash Flow per Share Historical Data
The historical data trend for Theralase Technologies's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Theralase Technologies Operating Cash Flow per Share Chart
Competitive Comparison of Theralase Technologies's Operating Cash Flow per Share
For the Medical Devices subindustry, Theralase Technologies's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theralase Technologies's Price-to-Operating-Cash-Flow Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Theralase Technologies's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralase Technologies Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Theralase Technologies's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSXV:TLT has been successfully added to your 